Literature DB >> 20196806

Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents.

J Grebely1, J D Raffa, C Lai, T Kerr, B Fischer, M Krajden, G J Dore, M W Tyndall.   

Abstract

The aim of this study was to measure the impact of hepatitis C virus (HCV) infection on mortality in a cohort of inner city residents. The Community Health and Safety Evaluation is a community-based study of inner city residents followed retrospectively and prospectively through linkages with provincial virology and mortality databases. We identified participants having received HCV antibody testing, evaluated cause-specific mortality rates and factors associated with all-cause and liver-related mortality using Cox Proportional Hazards models. Overall, 2332 participants received HCV antibody testing (recent non-injection drug use - 81%). The prevalence of HCV and HIV was 64% (1495 of 2332) and 21% (485 of 2332), respectively. Between January 2003 and December 2007, there were 180 deaths (192 per 10.000 person-years; 95% CI: 165, 222), with 21% HIV-related, 20% drug-related and 7% liver-related. Mortality was associated with age >50 [adjusted hazard ratio (AHR) 2.80 vs < 40 years (referent group); 95% CI 1.93, 4.07, P < 0.001] and HIV infection (AHR 3.81; 95% CI 2.72, 5.34, P < 0.001), but not positive HCV antibody status (AHR 1.19; 95% CI 0.83, 1.72, P = 0.35). Liver-related mortality was associated with age >50 [AHR 18.49 vs < 40 years (referent group); 95% CI 2.27, 150.41, P < 0.001] and positive HCV antibody status (AHR 7.69; 95% CI 0.99, 59.98, P = 0.052). This study demonstrates a high rate of mortality in this population, particularly those with HIV. HCV-infected inner city residents >50 years of age were at significant risk of liver-related mortality. Continued surveillance of this population infected with HCV in the 1970s and 1980s is important.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20196806     DOI: 10.1111/j.1365-2893.2010.01279.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  26 in total

1.  Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.

Authors:  Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

2.  Changes in blood-borne infection risk among injection drug users.

Authors:  Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

Review 3.  Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics.

Authors:  Lynn E Taylor
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-07-21

4.  Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui
Journal:  Addiction       Date:  2013-10-24       Impact factor: 6.526

5.  Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.

Authors:  Ashly E Jordan; David C Perlman; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; Denis Nash
Journal:  J Clin Virol       Date:  2020-01-27       Impact factor: 3.168

6.  Community-based participatory research in a heavily researched inner city neighbourhood: Perspectives of people who use drugs on their experiences as peer researchers.

Authors:  Will Damon; Cody Callon; Lee Wiebe; Will Small; Thomas Kerr; Ryan McNeil
Journal:  Soc Sci Med       Date:  2017-01-21       Impact factor: 4.634

7.  Clinical variables identify seronegative HCV co-infection in HIV-infected individuals.

Authors:  Ajay R Bharti; Scott L Letendre; Tanya Wolfson; David Clifford; Ann C Collier; Benjamin Gelman; Justin McArthur; Christina Marra; Allen McCutchan; Susan Morgello; David Simpson; Ron J Ellis; Igor Grant
Journal:  J Clin Virol       Date:  2011-09-15       Impact factor: 3.168

Review 8.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 9.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

10.  HIV Serostatus and Having Access to a Physician for Regular Hepatitis C Virus Care Among People Who Inject Drugs.

Authors:  Tara Beaulieu; Kanna Hayashi; Michael J Milloy; Ekaterina Nosova; Kora DeBeck; Julio Montaner; Thomas Kerr; Lianping Ti
Journal:  J Acquir Immune Defic Syndr       Date:  2018-05-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.